Close Menu

NEW YORK (GenomeWeb) – Gene editing technology company Inscripta announced today that its existing investors have agreed to contribute an additional $30 million to its Series C funding round, bringing the total raised in the round to $85.5 million.

In February, the company said it had raised $55.5 million from Venrock, Foresite, Mérieux Développement, Paladin Capital Group, MLS Capital, and NanoDimension. The same investors contributed the additional funding.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Master's and doctoral students in the UK call on funding groups to extend their grants for the duration of the disruption caused by the COVID-19 outbreak, the Guardian reports.

Squid can make edits to their RNA within the cytoplasm of their axons, Science News reports.

The Chan Zuckerberg Initiative is putting $25 million toward COVID-19 treatment research, according to the Verge.

In Science this week: researchers engineer version of Cas9 that is nearly PAM-less, and more.